Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Dianthus Therapeutics Inc’s stock clocked out at $38.19, up 0.18% from its previous closing price of $38.12. In other words, the price has increased by $0.18 from its previous closing price. On the day, 0.92 million shares were traded. DNTH stock price reached its highest trading level at $39.34 during the session, while it also had its lowest trading level at $37.96.
Ratios:
To gain a deeper understanding of DNTH’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.35 and its Current Ratio is at 17.35. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Truist on October 14, 2025, initiated with a Buy rating and assigned the stock a target price of $56.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 04 ’25 when Savitz Ryan sold 20,000 shares for $45.18 per share. The transaction valued at 903,600 led to the insider holds 0 shares of the business.
RYAN SAVITZ bought 20,000 shares of DNTH for $879,400 on Dec 04 ’25. On Nov 14 ’25, another insider, Randhawa Simrat, who serves as the EVP, Head of R&D of the company, sold 109,031 shares for $38.14 each. As a result, the insider received 4,158,442 and left with 4,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNTH now has a Market Capitalization of 1637435008 and an Enterprise Value of 1236107008. For the stock, the TTM Price-to-Sale (P/S) ratio is 530.66 while its Price-to-Book (P/B) ratio in mrq is 2.99. Its current Enterprise Value per Revenue stands at 401.594 whereas that against EBITDA is -8.817.
Stock Price History:
The Beta on a monthly basis for DNTH is 1.59, which has changed by 0.6575521 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, DNTH has reached a high of $45.46, while it has fallen to a 52-week low of $13.36. The 50-Day Moving Average of the stock is -4.94%, while the 200-Day Moving Average is calculated to be 36.80%.
Shares Statistics:
It appears that DNTH traded 651.02K shares on average per day over the past three months and 559580 shares per day over the past ten days. A total of 42.85M shares are outstanding, with a floating share count of 36.43M. Insiders hold about 15.04% of the company’s shares, while institutions hold 92.73% stake in the company. Shares short for DNTH as of 1765756800 were 4164492 with a Short Ratio of 6.40, compared to 1763078400 on 4082790. Therefore, it implies a Short% of Shares Outstanding of 4164492 and a Short% of Float of 11.26.
Earnings Estimates
Dianthus Therapeutics Inc (DNTH) is currently under the scrutiny of 7.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$1.03, with high estimates of -$0.99 and low estimates of -$1.07.
Analysts are recommending an EPS of between -$3.38 and -$4.74 for the fiscal current year, implying an average EPS of -$3.73. EPS for the following year is -$3.87, with 6.0 analysts recommending between -$3.13 and -$4.52.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for DNTH’s current fiscal year. The highest revenue estimate was $3.14M, while the lowest revenue estimate was $1.75M, resulting in an average revenue estimate of $2.22M. In the same quarter a year ago, actual revenue was $6.24M
